浙江省2010～2014年甲型肝炎疫苗疑似预防接种异常反应监测分析

发布时间：2017-12-28 14:33

本文关键词：浙江省2010～2014年甲型肝炎疫苗疑似预防接种异常反应监测分析　出处：《中国疫苗和免疫》2015年06期 　论文类型：期刊论文

【摘要】：目的分析浙江省2010~2014年甲型肝炎(甲肝)减毒活疫苗(HepA-L)和甲肝灭活疫苗(HepA-I)的疑似预防接种异常反应(adverse events following immunization,AEFI)监测资料,了解甲肝疫苗AEFI发生和分布情况,初步探讨其预防接种安全性。方法通过中国AEFI信息管理系统和浙江省免疫规划信息系统获取AEFI监测数据及接种数据,对HepA-L和HepA-I的AEFI发生情况进行分析。结果 2010~2014年浙江省HepA-L AEFI报告395例,男女性别比为2.0∶1,7岁者占99.49%,报告县(区)比例为87.8%;HepA-I AEFI报告108例,男女性别比为1.3∶1,7岁者占96.30%,报告县(区)比例为45.6%;两种疫苗AEFI报告均以第2、3季度居多。HepA-L AEFI报告发生率为14.39/10万剂,一般反应为9.98/10万剂,异常反应为3.71/10万剂;HepA-I AEFI报告发生率为9.72/10万剂,一般反应为7.74/10万剂,异常反应为1.71/10万剂。HepA-L和HepA-I AEFI报告例数和报告发生率均呈现逐年上升趋势。一般反应以发热、红肿、硬结为主,异常反应以过敏性皮疹为主;均主要集中在接种后≤1d发生。HepA-L和HepA-I AEFI分别有99.2%、100%治愈或好转,均无死亡报告。结论浙江省HepA-L和HepA-I的安全性均在可接受范围内;HepA-L AEFI报告发生率稍高于HepA-I;AEFI监测敏感性逐年提高。
[Abstract]:Objective to analyze the 2010~2014 in Zhejiang province hepatitis A (HAV) live attenuated vaccine (HepA-L) and inactivated hepatitis A vaccine (HepA-I) suspected abnormal reaction to vaccination (adverse events following immunization, AEFI) monitoring data, to understand the occurrence and distribution of hepatitis A vaccine AEFI situation, to explore the safety of vaccination. Methods the AEFI monitoring data and vaccination data were obtained through the Chinese AEFI information management system and Zhejiang immunization planning information system, and the occurrence of AEFI in HepA-L and HepA-I was analyzed. Results 395 cases of 2010~2014 in Zhejiang province HepA-L AEFI report, the sex ratio was 2 1,7 years old accounted for 99.49%, the report of the county (District) accounted for 87.8%; 108 cases of HepA-I AEFI report, the sex ratio was 1.3 1,7 years old accounted for 96.30%, the report of the county (District) accounted for 45.6%; two kinds of vaccine AEFI report the majority are in the second, third quarter. The incidence of HepA-L AEFI reports is 14.39/10 10000, the general response is 9.98/10 million, the abnormal reaction is 3.71/10 million, the incidence of HepA-I AEFI report is 9.72/10 million, the general response is 7.74/10 million, and the abnormal reaction is 1.71/10 million. The number of reports and the incidence of reports in HepA-L and HepA-I AEFI are increasing year by year. The general reaction with fever, redness, induration, abnormal reactions to allergic rash; are mainly concentrated in less than 1D after inoculation. HepA-L and HepA-I AEFI were cured or improved in 99.2%, 100%, and no deaths were reported. Conclusion the safety of HepA-L and HepA-I in Zhejiang province is acceptable. The incidence of HepA-L AEFI report is slightly higher than that of HepA-I, and the sensitivity of AEFI monitoring is increasing year by year.
【作者单位】：浙江省疾病预防控制中心;
【分类号】：R186
【正文快照】： 甲型肝炎(甲肝)是一种主要以粪-口途径传播的病毒感染性疾病,潜伏期为15~50天,平均潜伏期为28天[1-3],在许多发展中国家,80%以上的青少年病毒性肝炎为甲肝病毒感染,而且在发达国家也较为常见[4-6]。目前全球使用的甲肝疫苗有两种:甲肝灭活疫苗(Hepatitis A Inactivated Vaccin

【相似文献】